Business Context and Reporting Period
Company: AYTU BIOSCIENCE, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: March 31, 2017
Event Date: March 31, 2017
The registrant reported the entry into a Material Definitive Agreement and the completion of an asset disposition involving its product line.
Key Financial Metrics
Transaction Proceeds: $1,750,000 received at closing.
Asset Sold: All assets related to "Primsol" (trimethoprim solution), including intellectual property, contracts, inventory, work in process, and marketing materials.
Liabilities: The company retains liabilities associated with the Primsol Asset that occurred prior to the closing date.
Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
- Asset Disposition: Sold the Primsol Asset to Allegis Holdings, LLC.
- Non-Compete Restriction: The company agreed to a 24-month non-compete clause, prohibiting the sale, marketing, or distribution of any liquid urinary tract anti-infective product containing trimethoprim worldwide.
- Significance: Management evaluated the transaction and concluded it is not significant to the company's overall business.
Outlook, Risks, and Contingencies
Management Commentary: The transaction was deemed not significant to the business. The agreement includes customary representations, warranties, and indemnification provisions for breaches and liabilities related to the asset pre- and post-closing.
Risks/Contingencies: The company remains liable for pre-closing liabilities associated with the Primsol Asset. The full text of the agreement, filed as an exhibit to the Form 10-Q, contains the complete terms and limitations.
Investor Verification Checklist
- Verify the exact scope of liabilities retained by AYTU Bioscience regarding pre-closing Primsol operations.
- Confirm the impact of the 24-month non-compete restriction on future product development or partnerships in the urinary tract anti-infective space.
- Review the full Asset Purchase Agreement filed as an exhibit to the Form 10-Q for the quarter ended March 31, 2017.
- Check the press release (Exhibit 99.1) for additional details on the strategic rationale for the sale.